AAUM (Average Assets Under Management) of ₹94.08 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 65.2% | 64.7% | ▼ -0.5% |
| Healthcare Services | 25.8% | 26.9% | ▲ +1.2% |
| Chemicals & Petrochemicals | 3.1% | 3.1% | ● 0.0% |
| Insurance | 1.2% | 1.0% | ▼ -0.1% |
| Retailing | 0.7% | 0.7% | ● -0.1% |
| IT - Services | 0.5% | 0.5% | ● -0.1% |
| Financial Technology (Fintech) | 1.4% | 0.0% | ▼ -1.4% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 64.7% | 63.1% | ▼ -1.6% |
| Healthcare Services | 26.9% | 27.5% | ▲ +0.6% |
| Chemicals & Petrochemicals | 3.1% | 2.8% | ▼ -0.3% |
| Insurance | 1.0% | 0.9% | ▼ -0.1% |
| Retailing | 0.7% | 0.7% | ● +0.0% |
| IT - Services | 0.5% | 0.5% | ● +0.0% |
Comparing Jun 2026 → Jul 2026
| # | Stock | Sector | Weight (Jul 2026) |
|---|---|---|---|
| 1 | Jupiter Life Line Hospitals Limited ₹2.48 Cr |
Healthcare Services | 2.23% |
| 2 | Manipal Health Enterprises Ltd ₹1.08 Cr |
Healthcare Services | 0.96% |
| # | Stock | Sector | Last Weight (Jun 2026) |
|---|---|---|---|
| 1 | JB Chemicals & Pharmaceuticals Limited ₹6.61 Cr |
Pharmaceuticals & Biotechnology | 6.40% |
| 2 | Dr. Reddy's Laboratories Limited ₹2.72 Cr |
Pharmaceuticals & Biotechnology | 2.63% |
| 3 | Jupiter Life Line Hospitals Ltd ₹2.13 Cr |
Healthcare Services | 2.06% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | Torrent Pharmaceuticals Limited ₹10.47 Cr |
Pharmaceuticals & Biotechnology | 2.58% | 9.38% | +6.80% |
| 2 | Divi's Laboratories Limited ₹11.55 Cr |
Pharmaceuticals & Biotechnology | 9.14% | 10.35% | +1.21% |
| 3 | Dr. Lal Path Labs Limited ₹4.52 Cr |
Healthcare Services | 3.10% | 4.05% | +0.95% |
| 4 | Abbott India Limited ₹3.61 Cr |
Pharmaceuticals & Biotechnology | 2.56% | 3.23% | +0.67% |
| 5 | Pfizer Limited ₹2.52 Cr |
Pharmaceuticals & Biotechnology | 1.65% | 2.25% | +0.60% |
| 6 | Lenskart Solutions Limited ₹75.79 L |
Retailing | 0.67% | 0.68% | +0.01% |
| 7 | Sagility Limited ₹53.22 L |
IT - Services | 0.47% | 0.48% | +0.01% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | Max Healthcare Institute Limited ₹6.54 Cr |
Healthcare Services | 6.52% | 5.86% | -0.66% |
| 2 | Mankind Pharma Limited ₹5.20 Cr |
Pharmaceuticals & Biotechnology | 5.19% | 4.66% | -0.53% |
| 3 | Ajanta Pharma Limited ₹5.81 Cr |
Pharmaceuticals & Biotechnology | 5.56% | 5.20% | -0.36% |
| 4 | Krishna Institute Of Medical Sciences Limited ₹4.20 Cr |
Healthcare Services | 4.12% | 3.77% | -0.35% |
| 5 | Rubicon Research Limited ₹4.11 Cr |
Pharmaceuticals & Biotechnology | 3.99% | 3.68% | -0.31% |
| 6 | Navin Fluorine International Limited ₹3.14 Cr |
Chemicals & Petrochemicals | 3.09% | 2.81% | -0.28% |
| 7 | Aster DM Healthcare Limited ₹6.94 Cr |
Healthcare Services | 6.41% | 6.21% | -0.20% |
| 8 | Cipla Limited ₹2.67 Cr |
Pharmaceuticals & Biotechnology | 2.57% | 2.39% | -0.18% |
| 9 | Neuland Laboratories Limited ₹3.38 Cr |
Pharmaceuticals & Biotechnology | 3.19% | 3.03% | -0.16% |
| 10 | ICICI Lombard General Insurance Company Limited ₹99.34 L |
Insurance | 1.03% | 0.89% | -0.14% |
29 stocks — Jul 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹12.12 Cr |
Pharmaceuticals & Biotechnology |
10.86%
|
|
| 2 |
₹11.55 Cr |
Pharmaceuticals & Biotechnology |
10.35%
|
|
| 3 |
₹10.47 Cr |
Pharmaceuticals & Biotechnology |
9.38%
|
|
| 4 |
₹6.94 Cr |
Healthcare Services |
6.21%
|
|
| 5 |
₹6.54 Cr |
Healthcare Services |
5.86%
|
|
| 6 |
₹5.81 Cr |
Pharmaceuticals & Biotechnology |
5.20%
|
|
| 7 |
₹5.20 Cr |
Pharmaceuticals & Biotechnology |
4.66%
|
|
| 8 |
₹4.52 Cr |
Healthcare Services |
4.05%
|
|
| 9 |
₹4.20 Cr |
Healthcare Services |
3.77%
|
|
| 10 |
₹4.11 Cr |
Pharmaceuticals & Biotechnology |
3.68%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.